1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Summary: The fiscal year 2026 (FY26) Kidney Cancer Research Program (KCRP) Concept Award supports highly innovative, untested, potentially groundbreaking concepts, theories, paradigms and/or basic kidney cancer research. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation in kidney cancer. Applications must describe how the new concept will be innovative and present a novel course of investigation in the field of kidney cancer. Distinctive Features: • Preliminary data are not allowed. • This is a blinded funding mechanism. Applications to this funding opportunity will undergo a double-blinded peer review. Applications must not include any materials that may identify the Principal Investigator (PI), a collaborator, or the organization of the PI or collaborator. • Due to the blinded nature of the review process, identifying or making references to the PI, collaborator(s), or their organization(s) in the proposal (Project Narrative, List of Abbreviations, Acronyms, Symbols, Statement of Work, Impact Statement and Innovation Statement) is prohibited and will result in administrative rejection of the application.
Funding Opportunity Number: HT942526KCRPCA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $840K total program funding.
Get alerted about grants like this
Get emailed when new opportunities from “Defense Health Agency Contracting Activity - DHACA” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Eligible applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility. Confirm the full requirements in the official notice before applying.
The current listing shows $840K total program funding. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for DoW Kidney Cancer, Concept Award are due July 28, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Yes — DoW Kidney Cancer, Concept Award is offered by Defense Health Agency Contracting Activity - DHACA and this listing comes from Grants.gov, an official U.S. federal source. Federal applications generally require registrations (for example SAM.gov or an agency submission portal), so allow extra lead time.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
DoW Peer Reviewed Medical, Research Advancement Award is sponsored by Defense Health Agency Contracting Activity - DHACA. Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Research Advancement Award supports fundamental research studies that will make an important contribution towards research, patient care, and/or quality of life for a disease or condition related…
Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Discovery Award supports novel, untested, high-risk, high-reward research projects with the potential to provide new insights, paradigms, technologies, or applications and with a potential to generate preliminary data that will lay the foundation for future projects. The application must address a critical problem or question in the field of research and/or patient care in a congressionally directed FY26 PRMRP topic area and one of the FY26 PRMRP portfolio-specific strategic goals.Distinctive Features: Applications must not include preliminary data. The focus of this award mechanism is innovation. Research proposed to this mechanism should be pioneering and revolutionary, and the outcomes generated by the award are expected to generate robust preliminary data that will lay the groundwork for future avenues of scientific investigation or product development.Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $11.165M to fund approximately 29 Discovery Award applications with total cost caps of $385,000 per award. The maximum period of performance is 2 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027. Funding Opportunity Number: HT942526PRMRPDA. Assistance Listing: 12.420. Funding Instrument: CA,G. Category: ST. Award Amount: $11.2M total program funding.
Summary: The fiscal year 2026 (FY26) Kidney Cancer Research Program (KCRP) Concept Award supports highly innovative, untested, potentially groundbreaking concepts, theories, paradigms and/or basic kidney cancer research. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation in kidney cancer. Applications must describe how the new concept will be innovative and present a novel course of investigation in the field of kidney cancer. Distinctive Features: • Preliminary data are not allowed. • This is a blinded funding mechanism. Applications to this funding opportunity will undergo a double-blinded peer review. Applications must not include any materials that may identify the Principal Investigator (PI), a collaborator, or the organization of the PI or collaborator. • Due to the blinded nature of the review process, identifying or making references to the PI, collaborator(s), or their organization(s) in the proposal (Project Narrative, List of Abbreviations, Acronyms, Symbols, Statement of Work, Impact Statement and Innovation Statement) is prohibited and will result in administrative rejection of the application. Funding Opportunity Number: HT942526KCRPCA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $840K total program funding.
AACR-Kure It Research Grant for Immunotherapy in Kidney Cancer is sponsored by American Association for Cancer Research (AACR). This grant supports immunotherapy research in kidney cancer. Grant funds may be used for investigator and collaborator salaries (up to 25% of budget), postdoctoral fellows, graduate students, research assistants, lab supplies, equipment, publication fees, and travel.
Elevance Health Foundation's maternal/infant health RFP closes July 31, 2026, part of a five-year, $150 million commitment. Last cycle it awarded 29 grants totaling $6.5M across the pregnancy continuum. Here is what the funder actually rewards — measurable disparity reduction, a 15% indirect-cost cap, and scalable models — plus how nonprofits in the 10 priority states should frame a competitive proposal.
Read articleThe Elevance Health Foundation's Maternal/Infant Health RFP funds nonprofits — up to ~$1M over 1-3 years — working to close disparities across the full pregnancy journey. Applications close July 31, 2026, with a national track and a local track in ten named states. Here's how the funder thinks, what 'measurable outcomes' really means here, and how to build a proposal that clears the bar.
Read articleARPA-H's 2026 SBIR/STTR BAA opens seven transformative health topics with $600K Phase I and $3.5M Phase II contracts — non-dilutive, milestone-driven money. The July 10 Solution Summary gate decides who ever gets to pitch. Here's how the ARPA-H model differs from NIH and how small health-tech firms actually get through the funnel.
Read article